CDC Advises on Limited Nirsevimab Supply and RSV Protection Options
The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
United States Marina Demidiuk Sanofi Beyfortus Children Program Centers For Disease Health Alert Network Advisory
Source: infectioncontroltoday.com